Skip to main content
Erschienen in:

27.01.2022 | Original Article – Cancer Research

CXCL12/CXCR4 axis gene variants contribute to an increased vulnerability to HPV infection and cervical oncogenesis

verfasst von: Nádia Calvo Martins Okuyama, Fernando Cezar-dos-Santos, Kleber Paiva Trugilo, Aline Esposito, Roberta Losi Guembarovski, José d’Oliveira Couto-Filho, Maria Angelica Ehara Watanabe, Karen Brajão de Oliveira

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Every year, more than half a million women are diagnosed with cervical cancer (CC). Individual factors may contribute to the cervical cancer development, such as immunogenetic variation. CXCL12/CXCR4 axis is involved in tumor progression and aggressiveness. In the present study, we aimed to investigate a possible association between two single-nucleotide variants (CXCL12 rs1801157 and CXCR4 rs2228014) with HPV infection and cervical cancer development.

Methods

PCR technique was used to test HPV positivity in 424 women, in which the allelic frequency of CXCL12 rs1801157 and CXCR4 rs2228014 was also assessed by PCR-restriction fragment length polymorphism.

Results

CXCL12 rs1801157 was associated with HPV infection in the allelic distribution as well in the codominant, dominant and recessive genetic models; as well with squamous intraepithelial lesions (SIL) and CC in the codominant and dominant models. CXCR4 rs2228014 was associated to HPV infection in the codominant model and allelic distribution; as well with SIL/CC in the codominant, dominant and allelic models. Independent associations were found for CXCL12 AA genotype and HPV infection, SIL and CC development, as well as, CXCR4 allele T and HPV infection and CC. The variants interaction analysis demonstrated that the presence of both polymorphisms increases the susceptibility of HPV infection in 10.1 times, SIL (2 times) and CC development in 4.2 times.

Conclusions

This is the first study demonstrating that the interaction of CXCL12 and CXCR4 variants contributes to the increased susceptibility of HPV infection, squamous intraepithelial lesions and cervical cancer development.
Literatur
Zurück zum Zitat Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London, p 1991 Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London, p 1991
Zurück zum Zitat Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4(7):540–50. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4(7):540–50.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
Zurück zum Zitat Butrym A, Gebura K, Iwaszko M et al (2016) Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia. HLA 87(6):432–438PubMedCrossRef Butrym A, Gebura K, Iwaszko M et al (2016) Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia. HLA 87(6):432–438PubMedCrossRef
Zurück zum Zitat Chang SC, Lin PC, Yang SH et al (2009) SDF-1alpha G801A polymorphism predicts lymph node metastasis in stage T3 colorectal cancer. Ann Surg Oncol 16(8):2323–2330PubMedCrossRef Chang SC, Lin PC, Yang SH et al (2009) SDF-1alpha G801A polymorphism predicts lymph node metastasis in stage T3 colorectal cancer. Ann Surg Oncol 16(8):2323–2330PubMedCrossRef
Zurück zum Zitat Chang SF, Li SL, Yang B et al (2015) CXCL12 G801A polymorphism and susceptibility to glioma: a case-control study. Genet Mol Res 14(4):17399–17405PubMedCrossRef Chang SF, Li SL, Yang B et al (2015) CXCL12 G801A polymorphism and susceptibility to glioma: a case-control study. Genet Mol Res 14(4):17399–17405PubMedCrossRef
Zurück zum Zitat Clopper C, Pearson ES (1934) Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404–413CrossRef Clopper C, Pearson ES (1934) Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404–413CrossRef
Zurück zum Zitat Colpani V, Falcetta FS, Bidionotto AB et al (2020) Prevalence of human papillomavirus (HPV) in Brazil: a systematic review and meta-analysis. PLoS ONE 15(2):e0229154PubMedPubMedCentralCrossRef Colpani V, Falcetta FS, Bidionotto AB et al (2020) Prevalence of human papillomavirus (HPV) in Brazil: a systematic review and meta-analysis. PLoS ONE 15(2):e0229154PubMedPubMedCentralCrossRef
Zurück zum Zitat Da Silva MC, Martins RPH, De Souza JL et al (2012) Prevalence of HPV infection and genotypes in women with normal cervical cytology in the state of Paraná, Brazil. Arch Gynecol Obstet 286(4):1015–1022PubMedCrossRef Da Silva MC, Martins RPH, De Souza JL et al (2012) Prevalence of HPV infection and genotypes in women with normal cervical cytology in the state of Paraná, Brazil. Arch Gynecol Obstet 286(4):1015–1022PubMedCrossRef
Zurück zum Zitat De Oliveira KB, Guembarovski RL, Oda JMM et al (2011) CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine 55(2):260–265PubMedCrossRef De Oliveira KB, Guembarovski RL, Oda JMM et al (2011) CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine 55(2):260–265PubMedCrossRef
Zurück zum Zitat Deng N, Zhou H, Fan H et al (2016) Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8(66):110635–110649CrossRef Deng N, Zhou H, Fan H et al (2016) Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8(66):110635–110649CrossRef
Zurück zum Zitat Deng P, Zuo Y, Feng S et al (2018) Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating hippo pathway. Life Sci 215:73–79PubMedCrossRef Deng P, Zuo Y, Feng S et al (2018) Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating hippo pathway. Life Sci 215:73–79PubMedCrossRef
Zurück zum Zitat Fu OY, Chang WH, Lin YD et al (2016) Breast cancer-associated high-order SNP-SNP interaction of CXCL12/CXCR4-related genes by an improved multifactor dimensionality reduction (MDR-ER). Oncol Rep 6(3):1739–1747CrossRef Fu OY, Chang WH, Lin YD et al (2016) Breast cancer-associated high-order SNP-SNP interaction of CXCL12/CXCR4-related genes by an improved multifactor dimensionality reduction (MDR-ER). Oncol Rep 6(3):1739–1747CrossRef
Zurück zum Zitat García-Moruja C, Alonso-lobo JM, Rueda P et al (2005) Functional characterization of SDF-1 proximal promoter. J Mol Biol 348(1):43–62PubMedCrossRef García-Moruja C, Alonso-lobo JM, Rueda P et al (2005) Functional characterization of SDF-1 proximal promoter. J Mol Biol 348(1):43–62PubMedCrossRef
Zurück zum Zitat Guembarovski A, Guembarovski RL, Hirata BKB et al (2018) CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer. Mol Biol Rep 45(5):741–775PubMedCrossRef Guembarovski A, Guembarovski RL, Hirata BKB et al (2018) CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer. Mol Biol Rep 45(5):741–775PubMedCrossRef
Zurück zum Zitat Guyon A (2014) CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Fronti Cell Neurosci 8:65 Guyon A (2014) CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Fronti Cell Neurosci 8:65
Zurück zum Zitat Halstead AM, Capadia CD, Bolzenius J et al (2017) Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife 16:1–2 Halstead AM, Capadia CD, Bolzenius J et al (2017) Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife 16:1–2
Zurück zum Zitat Hirata H, Hinoda Y, Kikuno N et al (2007) CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 13(17):5056–5062PubMedCrossRef Hirata H, Hinoda Y, Kikuno N et al (2007) CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 13(17):5056–5062PubMedCrossRef
Zurück zum Zitat Huang SJ, Tseng Y-K, Lo Y-H et al (2019) Association of SDF-1 and CXCR4 polymorphisms with susceptibility to oral and pharyngeal squamous cell carcinoma. Anticancer Res 39(6):2891–2902PubMedCrossRef Huang SJ, Tseng Y-K, Lo Y-H et al (2019) Association of SDF-1 and CXCR4 polymorphisms with susceptibility to oral and pharyngeal squamous cell carcinoma. Anticancer Res 39(6):2891–2902PubMedCrossRef
Zurück zum Zitat Kumar P, Mistri TK (2019) Transcription factors in SOX family: potent regulators for cancer initiation and development in the human body. Semin Cancer Biol 18:1–9 Kumar P, Mistri TK (2019) Transcription factors in SOX family: potent regulators for cancer initiation and development in the human body. Semin Cancer Biol 18:1–9
Zurück zum Zitat Lecavalier-Barsoum M, Chaudary N, Han K et al (2018) Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer. Int J Cancer 143(5):1017–1028PubMedCrossRef Lecavalier-Barsoum M, Chaudary N, Han K et al (2018) Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer. Int J Cancer 143(5):1017–1028PubMedCrossRef
Zurück zum Zitat Lin GT, Tseng H-F, Yanf CH et al (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS J Integr Biol 13(2):165–172CrossRef Lin GT, Tseng H-F, Yanf CH et al (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS J Integr Biol 13(2):165–172CrossRef
Zurück zum Zitat Maley SN, Schwartz SM, Johnson LG et al (2009) Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet 3(6):367–375CrossRef Maley SN, Schwartz SM, Johnson LG et al (2009) Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet 3(6):367–375CrossRef
Zurück zum Zitat Mortezaee K (2020) CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis. Life Sci 249:117534PubMedCrossRef Mortezaee K (2020) CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis. Life Sci 249:117534PubMedCrossRef
Zurück zum Zitat Okuyama KM, De Oliveira KB, Ariza CB et al (2015) Genetic polymorphism and expression of CXCR4 in breast cancer. Anal Cell Pathol 289510:1–8 Okuyama KM, De Oliveira KB, Ariza CB et al (2015) Genetic polymorphism and expression of CXCR4 in breast cancer. Anal Cell Pathol 289510:1–8
Zurück zum Zitat Okuyama NCM, Cezar-dos-Santos F, Pereira ER et al (2018) Genetic variant in CXCL12 gene raises susceptibility to HPV infection and squamous intraepithelial lesions development: a case-control study. J Biomed Sci 25:1–10CrossRef Okuyama NCM, Cezar-dos-Santos F, Pereira ER et al (2018) Genetic variant in CXCL12 gene raises susceptibility to HPV infection and squamous intraepithelial lesions development: a case-control study. J Biomed Sci 25:1–10CrossRef
Zurück zum Zitat Qin L-F, Qin J-M, Zhang J-Q et al (2018) CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol 14(13):1261–1271PubMedCrossRef Qin L-F, Qin J-M, Zhang J-Q et al (2018) CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol 14(13):1261–1271PubMedCrossRef
Zurück zum Zitat Roszak A, Misztal M, Sowińska A et al (2015) Stromal cell-derived factor- 1 G801A polymorphism and the risk factors for cervical cancer. Mol Med Rep 11:4633–4682PubMedCrossRef Roszak A, Misztal M, Sowińska A et al (2015) Stromal cell-derived factor- 1 G801A polymorphism and the risk factors for cervical cancer. Mol Med Rep 11:4633–4682PubMedCrossRef
Zurück zum Zitat Sethupathy P, Collins FS (2008) MicroRNA target site polymorphisms and human disease. Trends Genet 24(10):489–497PubMedCrossRef Sethupathy P, Collins FS (2008) MicroRNA target site polymorphisms and human disease. Trends Genet 24(10):489–497PubMedCrossRef
Zurück zum Zitat Shirozu M, Nakano T, Inazawa J et al (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1(SDF1) gene. Genomics 28:495–500PubMedCrossRef Shirozu M, Nakano T, Inazawa J et al (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1(SDF1) gene. Genomics 28:495–500PubMedCrossRef
Zurück zum Zitat Susek KH, Karvouni M, Alici E et al (2004) The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment. Front Immunol 25(9):2159 Susek KH, Karvouni M, Alici E et al (2004) The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment. Front Immunol 25(9):2159
Zurück zum Zitat Tee YT, Yang S-F, Wang P-H et al (2012) G801A polymorphism of human stromal cell-derived factor gene raises no susceptibility to neoplastic lesions of uterine cervix. Int J Gynecol Cancer 22(8):1297–1302PubMedCrossRef Tee YT, Yang S-F, Wang P-H et al (2012) G801A polymorphism of human stromal cell-derived factor gene raises no susceptibility to neoplastic lesions of uterine cervix. Int J Gynecol Cancer 22(8):1297–1302PubMedCrossRef
Zurück zum Zitat Torres-Poveda K, Burguete-García AI, Bahena-Román M et al (2016) Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study. BMC Cancer 24(16):330CrossRef Torres-Poveda K, Burguete-García AI, Bahena-Román M et al (2016) Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study. BMC Cancer 24(16):330CrossRef
Zurück zum Zitat Zanotta N, Tornesello ML, Annunziata C et al (2016) Candidate soluble immune mediators in young women with high-risk human papillomavirus infection: high expression of chemokines promoting angiogenesis and cell proliferation. PLoS ONE 11(3):1–14CrossRef Zanotta N, Tornesello ML, Annunziata C et al (2016) Candidate soluble immune mediators in young women with high-risk human papillomavirus infection: high expression of chemokines promoting angiogenesis and cell proliferation. PLoS ONE 11(3):1–14CrossRef
Zurück zum Zitat Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY, Xie X (2007) Study on CXCR4/ SDF-1 axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer 17:478–483PubMedCrossRef Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY, Xie X (2007) Study on CXCR4/ SDF-1 axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer 17:478–483PubMedCrossRef
Metadaten
Titel
CXCL12/CXCR4 axis gene variants contribute to an increased vulnerability to HPV infection and cervical oncogenesis
verfasst von
Nádia Calvo Martins Okuyama
Fernando Cezar-dos-Santos
Kleber Paiva Trugilo
Aline Esposito
Roberta Losi Guembarovski
José d’Oliveira Couto-Filho
Maria Angelica Ehara Watanabe
Karen Brajão de Oliveira
Publikationsdatum
27.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2022
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03884-0

Neu im Fachgebiet Onkologie

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.